Granzyme B cleaves tenascin-C to release its C-terminal domain in rheumatoid arthritis
Authors:
- Alexandre AubertAAAlexandre Aubert
- Amy LiuALAmy Liu
- Martin KaoMKMartin Kao
- Jenna GoeresJGJenna Goeres
- Katlyn C. RichardsonKRKatlyn C. Richardson
- Lorenz NiervesLNLorenz Nierves
- Karen JungKJKaren Jung
- Layla NabaiLNLayla Nabai
- Hongyan ZhaoHZHongyan Zhao
- Gertraud OrendGOGertraud Orend
- Roman KrawetzRKRoman Krawetz
- Philipp F. LangePLPhilipp F. Lange
Open Access
- 30 October 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (23)
Abstract
Rheumatoid arthritis (RA) is a common autoimmune disorder characterized by exacerbated joint inflammation. Despite the well-documented accumulation of the serine protease granzyme B (GzmB) in RA patient biospecimens, little is understood pertaining to its role in pathobiology. In the present study, tenascin-C (TNC) — a large, pro-inflammatory extracellular matrix glycoprotein — was identified as a substrate for GzmB in RA. GzmB cleaves TNC to generate 3 fragments in vitro: a 130 kDa fragment that remains anchored to the matrix and 2 solubilized fragments of 70 and 30 kDa. Mass spectrometry results suggested that the 30 kDa fragment contained the pro-inflammatory TNC C-terminal fibrinogen-like domain. In the synovial fluids of patients with RA, soluble levels of GzmB and TNC were significantly elevated compared with healthy controls. Further, immunoblotting revealed soluble 70 and 30 kDa TNC fragments in the synovial fluids of patients with RA, matching TNC fragment sizes generated by GzmB cleavage in vitro. Granzyme K (GzmK), another serine protease of the granzyme family, also cleaves TNC in vitro; however, the molecular weights of GzmK-generated TNC fragments did not correspond to TNC fragment sizes detected in patients. Our data support that GzmB, but not GzmK, contributes to RA through the cleavage of TNC.Keywords
Funding Information
- Canadian Institutes of Health Research (/)
- Michael Smith Health Research BC (/)
- Natural Sciences and Engineering Research Council of Canada (/)
- LEO Fondet (/)
- Arthritis Society (/)
This publication has 64 references indexed in Scilit:
- Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritisRheumatology, 2001
- Granzyme Activity in the Inflamed Lung Is Not Controlled by Endogenous Serine Proteinase InhibitorsThe Journal of Immunology, 2000
- The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodelingDevelopmental Dynamics, 2000
- Cleavage by Granzyme B Is Strongly Predictive of Autoantigen StatusJournal of Experimental Medicine, 1999
- Generation of Catalytically Active Granzyme K from Escherichia coli Inclusion Bodies and Identification of Efficient Granzyme K Inhibitors in Human PlasmaJournal of Biological Chemistry, 1999
- The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA)Clinical and Experimental Immunology, 1999
- Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re‐filling of the lytic granules and secretion of lytic proteins via a non‐granule pathwayEuropean Journal of Immunology, 1995
- Different Susceptibility of Small and Large Human Tenascin-C Isoforms to Degradation by Matrix MetalloproteinasesJournal of Biological Chemistry, 1995
- Granzyme‐positive cytotoxic cells are specifically increased in early rheumatoid synovial tissueArthritis & Rheumatism, 1994
- Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes.The Journal of Immunology, 1993